Biogen (BIIB) Total Debt Growth (3y) (2012 - 2025)
Biogen (BIIB) Total Debt Growth (3y) (2012 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Total Debt Growth (3y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
2.26% |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
31.94% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
1.29% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
1.29% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
16.90% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
-2.37% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
-4.22% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
21.55% |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
5.53% |
| 10 |
Biogen |
28.75 Bn |
24.47 Bn |
1.82 Bn |
- |
| Date | Value |
|---|
| Dec 31, 2025 |
0.03% |
| Dec 31, 2024 |
84.71% |
| Dec 31, 2022 |
61.33% |
| Dec 31, 2019 |
582.75% |
| Mar 31, 2018 |
0.47% |
| Dec 31, 2017 |
1.06% |
| Sep 30, 2017 |
462.54% |
| Jun 30, 2017 |
448.88% |
| Mar 31, 2017 |
440.80% |
| Dec 31, 2016 |
10.39% |
| Sep 30, 2016 |
13.12% |
| Jun 30, 2016 |
14.61% |
| Mar 31, 2016 |
-80.98% |
| Dec 31, 2015 |
-83.86% |
| Sep 30, 2015 |
-80.12% |
| Jun 30, 2015 |
-82.80% |
| Mar 31, 2015 |
-82.68% |
| Dec 31, 2014 |
-85.71% |
| Sep 30, 2014 |
-85.52% |
| Jun 30, 2014 |
-85.29% |
